OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Cherng on Approvals of Epcoritamab and Glofitamab for R/R DLBCL

May 8th 2024

Hua-Jay "Jeff" Cherng on approvals of epcoritamab and glofitamab for relapsed/refractory DLBCL

Dr Jurcic on the Evolution of Combination Therapies in the Management of Myelofibrosis

May 8th 2024

Joseph G. Jurcic, MD, discusses the evolution of combination therapies in the management of myelofibrosis.

Dr Beckermann on Targeting TREM2 in the Treatment of ccRCC

May 7th 2024

Kathryn Beckermann, MD, PhD, discusses ongoing studies investigating the role of TREM2 in the treatment of patients with clear cell renal cell carcinoma.

Dr Iyer on the Mechanism of Action of Imetelstat in Lower-Risk MDS

May 7th 2024

Sunil Iyer, MD, discusses the mechanism of action of imetelstat in patients with lower-risk myelodysplastic syndrome with anemia.

Dr Crane on the Ongoing Investigation of PARP Inhibitor Combinations in Ovarian Cancer

May 7th 2024

Dr Aldoss on the Utility of Ponatinib in Ph+ ALL

May 6th 2024

Ibrahim Aldoss, MD, discusses the utility of ponatinib in the phase 3 PhALLCON trial for patients with newly diagnosed, Ph+ acute lymphoblastic leukemia.

Dr Battiwalla on Advancements in the Multiple Myeloma Treatment Paradigm

May 6th 2024

Minoo Battiwalla, MD, discusses recent advancements in the multiple myeloma treatment paradigm.

Dr Siefker-Radtke on the Safety of Enfortumab Vedotin Plus Pembrolizumab in Bladder Cancer

May 6th 2024

Arlene O. Siefker-Radtke, MD, discusses toxicities associated with enfortumab vedotin plus pembrolizumab in patients with bladder cancer.

Dr Lenz on the Association Between HER2 Expression and Treatment Outcomes in mCRC

May 6th 2024

Heinz-Josef Lenz, MD, FACP, discusses the association between HER2 expression and treatment outcomes in metastatic colorectal cancer.

Dr Garje on Selecting Between PARP Inhibitor Combinations in mCRPC

May 4th 2024

Rohan Garje, MD, discusses considerations when choosing between FDA-approved PARP inhibitor–based combinations for patients with mCRPC.

Dr Deng on the Benefits of Pirtobrutinib in CLL

May 4th 2024

Changchun Deng, MD, PhD, discusses the mechanism of action and advantageous features of pirtobrutinib for patients with chronic lymphocytic leukemia.

Dr Merchán on the Future Treatment of Advanced RCC

May 3rd 2024

Jaime R. Merchán, MD, discusses the future treatment of patients with advanced renal cell carcinoma.

Dr Cobain on Future Considerations For the Treatment of HR+/HER2– Breast Cancer

May 3rd 2024

Erin Frances Cobain, MD, discusses key takeaways from an OncLive Institutional Perspectives in Cancer webinar on breast cancer.

Dr Tyson on the Phase 3 BOND-003 Trial in BCG-Unresponsive NMIBC With CIS

May 3rd 2024

Mark D. Tyson, II, MD, MPH, discusses findings from the phase 3 BOND-003 trial in BCG-unresponsive non–muscle-invasive bladder cancer with CIS.

Dr Iglesia on the COSMIC-312 Trial of Cabozantinib Plus Atezolizumab in HCC

May 3rd 2024

Michael Iglesia, MD, PhD, discusses outcomes from the phase 3 COSMIC-312 trial of first-line cabozantinib plus atezolizumab in hepatocellular carcinoma.

Dr Jagannath on the Patient Population in the LINKER-MM1 Trial in Multiple Myeloma

May 3rd 2024

Sundar Jagannath, MBBS, discusses the patient population evaluated in the LINKER-MM1 trial of linvoseltamab in relapsed/refractory multiple myeloma.

Dr Rosenberg on Toxicity Management With Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer

May 3rd 2024

Jonathan E. Rosenberg, MD, discusses toxicity management when administering enfortumab vedotin plus pembrolizumab in urothelial cancer.

Dr Garcia on the Future of the MELISA Trial in Ovarian Cancer

May 2nd 2024

Núria Agustí Garcia, MD, discusses the mapping of sentinel lymph nodes in early-stage ovarian cancer.

Dr Cobain on Endocrine Therapy–Based Treatment Strategies in HR+/HER2– Breast Cancer

May 2nd 2024

Erin Frances Cobain, MD, discusses optimal endocrine therapy–based treatment strategies in later-line settings for HR-positive/HER2-negative breast cancer.

Dr Lim on the Current Treatment Paradigm For Metastatic Pancreatic Cancer

May 2nd 2024

Kian-Huat Lim, MD, PhD, discusses the current treatment options for patients with metastatic pancreatic cancer.